

PATENT
U.S. Appln. No. 10/591,395
Intl. Appln. No. PCT/US2005/006588
Atty. Dkt. No. PP021431.0005

Express Mail Label No.: **EM 028420422 US** Date: **August 21, 2007**

IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

<i>In re</i> Application of:)	
)	Confirmation No.: 6065
Grandi and Ratti)	
)	Group Art Unit: 1645
Intl. Application No.: PCT/US2005/006588)	
U.S. Application No.: 10/591,395)	
)	
I.A. Filing date: March 2, 2005)	

For: IMMUNOGENIC COMPOSITIONS FOR CHLAMYDIA PNEUMONIAE

TRANSMITTAL LETTER

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In response to the "Notification of Missing Requirements Under 35 U.S.C. 371 in the United States Designated/Elected Office (DO/EO/US)", mailed May 22, 2007 from the United States Patent and Trademark Office, enclosed herewith are the following documents to complete the missing requirements in the above-identified application:


1. **COPY OF** Notification of Missing Requirements Under 35 U.S.C. 371 in the United States Designated/Elected Office (DO/EO/US).
2. **EXECUTED DECLARATION** (2 pages).
3. **NOTIFICATION THAT INVENTOR IS DECEASED.**
4. **SURCHARGE** – surcharge fee for Large Entity of \$130.00.
5. **TRANSMITTAL OF SEQUENCE LISTING INCLUDING:**
 - a. Statements under 37 C.F.R. 1.821-1.825 and 1.52(e)(4) and 1.821(f), including statement specifically directing entry of the Sequence Listing into the application.
 - b. Three (3) identical copies of the Sequence Listing in computer-readable form on compact disc.

6. **AMENDMENT** specifically directing entry of the Sequence Listing into the application.
7. **PETITION FOR EXTENSION OF TIME**
Applicants hereby petition to extend the time to respond to this Notification for one month (from July 22, 2007 to August 22, 2007) for a fee of \$120.00.
8. **PAYMENT** – The Commissioner is hereby authorized to charge Deposit Account No. 03-1664 in the amount of \$250.00 for the above fees.
9. **RETURN RECEIPT POSTCARD.**

The Commissioner is hereby authorized to charge any deficiency in fees or credit any overpayment associated with this communication and which may be required under 37 C.F.R. 1.16 and 1.17 to Deposit Account No. 03-1664.

Respectfully submitted,
NOVARTIS VACCINES AND DIAGNOSTICS, INC.

Date: August 21, 2007

By: 
Helen Lee
Registration No. 39,270

NOVARTIS VACCINES AND DIAGNOSTICS, INC.
Intellectual Property – R338
P.O. Box 8097
Emeryville, CA 94662-8097
Telephone: (510) 923-2192
Facsimile: (510) 655-3542

08/24/2007 GFREY1 00000107 031664 10591395

01 FC:1251 120.00 DA
02 FC:1617 130.00 DA



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/591,395	Guido Grandi	002441.00212

INTERNATIONAL APPLICATION NO.
PCT/US05/06588

I.A. FILING DATE	PRIORITY DATE
03/02/2005	03/02/2004

27476
 NOVARTIS VACCINES AND DIAGNOSTICS INC.
 CORPORATE INTELLECTUAL PROPERTY R338
 P.O. BOX 8097
 Emeryville, CA 94662-8097

CONFIRMATION NO. 9708

371 FORMALITIES LETTER

OC000000023975321

Date Mailed: 05/22/2007

NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as a Designated / Elected Office (37 CFR 1.495).

- Copy of the International Application filed on 09/01/2006
- Copy of the International Search Report filed on 09/01/2006
- Preliminary Amendments filed on 09/01/2006
- Information Disclosure Statements filed on 09/01/2006
- Request for Immediate Examination filed on 09/01/2006
- U.S. Basic National Fees filed on 09/01/2006
- Priority Documents filed on 09/01/2006
- Specification filed on 09/01/2006
- Claims filed on 09/01/2006
- Abstracts filed on 09/01/2006
- Drawings filed on 09/01/2006

The applicant needs to satisfy supplemental fees problems indicated below.

The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

- Oath or declaration of the inventors, in compliance with 37 CFR 1.497(a) and (b), identifying the application by the International application number and international filing date.
- To avoid abandonment, a surcharge (for late submission of filing fee, search fee, examination fee or oath or declaration) as set forth in 37 CFR 1.492(h) of \$130 for a non-small entity, must be submitted with the missing items identified in this letter.

SUMMARY OF FEES DUE:

Total additional fees required for this application is **\$130** for a Large Entity:

- **\$130 Surcharge.**

- This application clearly fails to comply with the requirements of 37 CFR. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", **as well as an amendment specifically directing its entry into the application.** Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- **For Rules Interpretation, call (571) 272-0951**
- **For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.**
- **Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov**

ALL OF THE ITEMS SET FORTH ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTHS FROM THE DATE OF THIS NOTICE OR BY 32 MONTHS FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

Registered users of EFS-Web may alternatively submit their reply to this notice via EFS-Web.
<https://portal.uspto.gov/authenticate/AuthenticateUserLocalEPF.html>

For more information about EFS-Web please call the USPTO Electronic Business Center at 1-866-217-9197 or visit our website at <http://www.uspto.gov/ebc>.

If you are not using EFS-Web to submit your reply, you must include a copy of this notice.

ANITA D JOHNSON

Telephone: (703) 308-9140 EXT 226

PART 2 - OFFICE COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/591,395	PCT/US05/06588	002441.00212

FORM PCT/DO/EO/905 (371 Formalities Notice)

PATENT

IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EP/US)

<i>In re</i> Application of:)	
)	Confirmation No.: 9708
Grandi and Ratti)	
)	Group Art Unit: 1653
Intl Application No.: PCT/US2005/006588)	
U.S. Application No.: 10/591,395)	
)	Atty. Dkt. No. PP021431.0005
I.A. Filing Date: March 2, 2005)	

For: IMMUNOGENIC COMPOSITIONS FOR CHLAMYDIA PNEUMONIAE

NOTIFICATION THAT INVENTOR IS DECEASED


Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This filing is to notify the U.S. Patent and Trademark Office that the inventor, Giulio Ratti, is deceased. The Assignee of the application desires to continue with the application. Attached are an Assignment and a Declaration For Patent Application for the above-referenced application.

Respectfully submitted,

NOVARTIS VACCINES AND DIAGNOSTICS, INC.

By: 
Helen Lee
Registration No. 39,270
Telephone: (510) 923-2192
Facsimile: (510) 655-3542

Date: August 21, 2007